Volume 24, Number 7—July 2018
Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 20151
|Variable||Adjusted OR (95% CI)||Adjusted p value|
|Concurrent medical conditions|
|No history of previous trauma||Referent|
|Previous trauma||9.78 (2.24–42.75)||0.002|
|No lipid disorder||Referent|
|Lipid disorder||2.73 (1.19–6.24)||0.017|
|No history of Infections||Referent|
|Recurrent or chronic infections‡||12.31 (3.86–39.22)||<0.0001|
|No history of dementia||Referent|
*Patients not at risk for IPD were defined as those without any recognized concurrent medical condition for which PPSV23 administration is recommended. IPD, invasive pneumococcal disease; OR, odds ratio; PPSV23, pneumococcal polysaccharide vaccine 23.
†Any concurrent medical condition, excluding those for which PPSV23 is recommended. Patients with these conditions were not included in the not at-risk group.
‡Various types of recurrent or chronic infections, including chronic otitis media, sinusitis, recurrent cellulitis, chronic osteomyelitis, and tuberculosis.
1Some results from this study were presented at the 10th International Symposium on Pneumococci and Pneumococcal Diseases, June 26–30, 2016, Glasgow, Scotland.
2Additional members of the Israeli Adult Invasive Pneumococcal Disease Group are listed at the end of this article.